Opinion|Videos|February 27, 2025
Balancing Treatment Intensity and Resistance Mechanisms in First-Line EGFR-mutated NSCLC: Amivantamab + Lazertinib vs Osimertinib Monotherapy
Author(s)Misako Nagasaka, MD, PhD
The panelist discusses how, Healthcare professionals use osimertinib 1L for EGFR-mutated NSCLC, re-testing at progression for resistance mutations. MARIPOSA data refine 1L choices by predicting resistance pathways, guiding optimal sequencing.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is your sequencing strategy/rationale for 1L and beyond in EGFR-mutated metastatic NSCLC?
- When would you re-test for new resistance mutations?
- How does recent evidence from MARIPOSA (resistance mechanisms analysis) influence what you would use upfront in 1L treatment?
Advertisement
Related to this article
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5